Build Your Own Vaccine Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Build Your Own Vaccine Facility
New modular bioprocessing technology could quicken the response to an outbreak of disease.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 14


Erik Greb
The recent outbreak of cholera in Haiti highlighted the urgent need, most acute in the developing world, for manufacturing capacity that can respond to pandemics rapidly. Modular technology under development by GE Healthcare (Waukesha, WI) and G-Con Manufacturing (College Station, TX) could provide a helpful solution.

The companies are combining GE Healthcare's single-use bioprocessing equipment and G-Con's cleanroom technology to create standard modular bioprocessing facilities (MBFs) that clients could fit with upstream or downstream utilities for their specific applications. If need be, users could refit MBFs with new equipment later without difficulty. Catarina Flyborg, general manager of bioprocess products at GE Healthcare, likens the technology to Legos that users can link to build manufacturing trains.

Each 18 25 ft unit could house as much as 2000 L of fermentation capacity. A set of air bearings underneath each MBF will ensure that personnel can physically move the units where they're needed. And, because each of the bioprocessing building blocks will be contained, clients will be able to install them in unclassified spaces.

The MBFs' modularity could help clients quickly set up a small-scale manufacturing facility in any location while requiring fewer capital expenses than building or renovating a facility would entail, says Flyborg. The new technology could make bioprocessing capacity more accessible than before and potentially help respond to emerging health crises quickly.

Erik Greb is an assistant editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here